Share Subscription into Incanthera plc (“Incanthera”)

29th September 2020 - 9:01 am

ImmuPharma PLC (LSE:IMM), (Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company, announces that further to a subscription agreement entered into at the time of Incanthera’s IPO onto AQSE Growth Market* in February 2020, ImmuPharma has now executed its subscription agreement to subscribe £250,000 for 2,631,579 ordinary shares of 2p each at a subscription price equal to Incanthera’s IPO price of 9.5p each.

Following this subscription, ImmuPharma will hold 9,904,319 shares in Incanthera, representing a 15.35% position in the enlarged share capital of Incanthera.

ImmuPharma notes two recent positive announcements from Incanthera regarding studies of its lead product Sol, a potentially innovative topical product for the treatment of solar keratosis and the prevention of skin cancers. These announcements can be viewed on Incanthera’s website:

Commenting on the announcement, Dimitri Dimitriou, ImmuPharma’s Chief Executive Officer said:“ImmuPharma is a strong supporter of Incanthera, sharing common goals of progressing both of our therapeutic pipelines to benefit the long term health of patients, globally.

 We are extremely pleased to note Incanthera’s two recent announcements, evidencing great progress towards its immediate goal of taking its lead product Sol to market.”

*Formerly known as NEX Exchange Growth Market

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014. (“MAR”).


To download announcement click here

Share this article